出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2020/07/13 17:41:44」(JST)
| Primary biliary cholangitis | |
|---|---|
| Other names | Primary biliary cirrhosis |
| Micrograph of PBC showing bile duct inflammation and injury. H&E stain. | |
| Specialty | Gastroenterology |
| Symptoms | Cholestasis, pruritus, fatigue |
| Complications | Cirrhosis, hepatic failure, portal hypertension |
| Usual onset | Usually middle-aged women |
| Causes | Autoimmune |
| Diagnostic method | Anti-mitochondrial antibodies, liver biopsy |
Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver.[1][2][3] It results from a slow, progressive destruction of the small bile ducts of the liver, causing bile and other toxins to build up in the liver, a condition called cholestasis. Further slow damage to the liver tissue can lead to scarring, fibrosis, and eventually cirrhosis.
Common symptoms are tiredness, itching and, in more advanced cases, jaundice. In early cases, there may only be changes in blood tests.[4]
PBC is a relatively rare disease, affecting up to 1 in 3,000–4,000 people.[5][6] It is much more common in women, with a sex ratio of at least 9:1 female to male.[1]
The condition has been recognised since at least 1851 and was named "primary biliary cirrhosis" in 1949.[7] Because cirrhosis is a feature only of advanced disease, a change of its name to "primary biliary cholangitis" was proposed by patient advocacy groups in 2014.[8][9]
People with PBC experience fatigue (80 percent): this is a non-specific symptom; it can be debilitating, with a huge impact on quality of life. Its pathogenesis is still unknown and it is quite challenging to explore its specificity and to treat. Comorbidities that could contribute or worse fatigue, such as depression, hypothyroidism, anaemia, obesity, or medication side effects, should be promptly identified and treated. Dry skin and dry eyes are also common. Itching (pruritus) occurs in 20–70 percent.[4] Pruritus can develop at any stage of the disease, it does not correlate with progression of liver disease, and may even improve or disappear as disease gets more advanced. It is usually reported by over 70% of patients, and it is typically mild-to-moderate in intensity. Given the impact on quality of life and night sleep, pruritus is correlated with fatigue. It can rarely be severe, non-responsive to medical therapy and requiring liver transplant. Pruritus is characteristically intermittent, worse at night, and improves during summer. People with more severe PBC may have jaundice (yellowing of the eyes and skin).[4] PBC impairs bone density and there is an increased risk of fracture.[4] Xanthelasma (skin lesions around the eyes) or other xanthoma may be present as a result of increased cholesterol levels.[10]
PBC can eventually progress to cirrhosis of the liver. This in turn may lead to a number of symptoms or complications:
People with PBC may also sometimes have the findings of an associated extrahepatic autoimmune disorder such as thyroid disease or rheumatoid arthritis or Sjögren's syndrome (in up to 80 percent of cases).[10][11]
PBC has an immunological basis, and is classified as an autoimmune disorder. It results from a slow, progressive destruction of the small bile ducts of the liver, with the intralobular ducts and the Canals of Hering (intrahepatic ductules) being affected early in the disease.
Most people with PBC (>90 percent) have anti-mitochondrial antibodies (AMAs) against pyruvate dehydrogenase complex (PDC-E2), an enzyme complex that is found in the mitochondria. People who are negative for AMAs are usually found to be positive when more sensitive methods of detection are used.[12]
People with PBC may also have been diagnosed with another autoimmune disease, such as a rheumatological, endocrinological, gastrointestinal, pulmonary, or dermatological condition, suggesting shared genetic and immune abnormalities.[11]
Common associations include Sjögren's syndrome, systemic sclerosis, rheumatoid arthritis, lupus, hypothyroidism and coeliac disease.[13][14]
A genetic predisposition to disease has been thought to be important for some time. Evidence for this includes cases of PBC in family members, identical twins both having the condition (concordance), and clustering of PBC with other autoimmune diseases. In 2009, a Canadian-led group of investigators reported in the New England Journal of Medicine results from the first PBC genome-wide association study.[15][16] This research revealed parts of the IL12 signaling cascade, particularly IL12A and IL12RB2 polymorphisms, to be important in the aetiology of the disease in addition to the HLA region. In 2012, two independent PBC association studies increased the total number of genomic regions associated to 26, implicating many genes involved in cytokine regulation such as TYK2, SH2B3 and TNFSF11.[17][18]
A study of over 2000 patients identified a gene - POGLUT1 - that appeared to be associated with this condition.[19] Earlier studies have also suggested that this gene may be involved. The implicated protein is an endoplasmic reticulum O-glucosyltransferase.
An environmental Gram negative alphabacterium — Novosphingobium aromaticivorans[20] has been associated with this disease with several reports suggesting an aetiological role for this organism.[21][22][23] The mechanism appears to be a cross reaction between the proteins of the bacterium and the mitochondrial proteins of the liver cells. The gene encoding CD101 may also play a role in host susceptibility to this disease.[24]
There is a failure of immune tolerance against the mitochondrial pyruvate dehydrogenase complex (PDC-E2), and this may also be the case with other proteins, including the gp210 and p62 nuclear pore proteins. Gp210 has increased expression in the bile duct of anti-gp210 positive patients, and these proteins may be associated with prognosis.[25]
Most patients are currently diagnosed when asymptomatic, having been referred to the hepatologist for abnormal liver function tests (mostly raised GGT or alkaline phosphatase [ALP]) performed for annual screening blood tests. Other frequent scenarios include screening of patients with non-liver autoimmune diseases, e.g. rheumatoid arthritis, or investigation of elevated cholesterol, evaluation of itch or unresolved cholestasis post-partum. Diagnosing PBC is generally straightforward. The basis for a definite diagnosis are reported below:
Given the high specificity of serological markers, liver biopsy is not necessary for the diagnosis of PBC; however, it is still necessary when PBC-specific antibodies are absent, or when co-existent autoimmune hepatitis (AIH) or non-alcoholic steatohepatitis (NASH) is suspected. Liver biopsy can be useful to stage the disease for fibrosis and ductopenia. Finally, it may also be appropriate in the presence of other extra-hepatic comorbidities.
Low magnification micrograph of PBC. H&E stain.
Intermediate magnification micrograph of PBC showing bile duct inflammation and periductal granulomas. Liver biopsy. H&E stain.
Immunofluorescence staining pattern of sp100 antibodies (nuclear dots) and AMA.
On microscopic examination of liver biopsy specimens, PBC is characterized by chronic, non-suppurative inflammation, which surrounds and destroys interlobular and septal bile ducts. These histopathologic findings in primary biliary cholangitis include the following:[30]
The Ludwig and Scheuer scoring systems have historically been used to stratify four (1–4) ‘stages’ of PBC, with stage 4 indicating the presence of cirrhosis. In the new system of Nakanuma, the stage of disease is based on fibrosis, bile duct loss and features of cholate-stasis, i.e. deposition of orcein-positive granules, whereas the grade of necroinflammatory activity is based on cholangitis and interface hepatitis. The accumulation of orcein-positive granules occurs evenly across the PBC liver, which means that staging using the Nakanuma system is more reliable regarding sampling variability.
Liver biopsy for the diagnosis and staging of PBC lost favour after the evidence of a patchy distribution of the duct lesions and fibrosis across the organ. The widespread availability of non-invasive measures of fibrosis means that liver biopsy for staging of PBC is somewhat obsolete.
Liver biopsy does, however, remain useful in certain settings. The main indications are to confirm the diagnosis of PBC when PBC-specific antibodies are absent and confirm a diagnosis of PBC with AIH features (i.e. overlap PBC-AIH). Liver biopsy is also useful to assess the relative contribution of each liver injury when a comorbid liver disease is present, such as non-alcoholic steatohepatitis. In patients with inadequate response to UDCA, liver biopsy may provide the explanation and could undoubtedly inform risk stratification. For example, it may identify a previously unsuspected variant syndrome, steatohepatitis, or interface hepatitis of moderate or greater severity. It is also useful in AMA and ANA-specific antibody negative cholestatic patients to indicate an alternative process, e.g. sarcoidosis, small duct PSC, adult idiopathic ductopenia.
Medical therapy of PBC targets disease progression and symptom control. The backbone of treatment of PBC is bile acid. UDCA has been the only drug available for two decades and more recently obeticholic acid (OCA), a semi-synthetic hydrophobic bile acid analogue, has been licensed in patients failing UDCA response or intolerant to UDCA. Several other agents have been studied, including immunosuppressants, but robust evidence of benefit is lacking.[10][31][32]
The introduction of UDCA has dramatically changed the pattern and the course of the disease. Numerous trials and observational studies have demonstrated its efficacy on liver biochemistry, histological progression and transplant-free survival [38]
Among the UDCA treated patients, the degree of the liver biochemistry improvement, i.e. the UDCA-response, identifies patients with different long-term prognosis. LT-free survival of patients with normal or near-normal liver biochemistry on UDCA is similar to that of the general population, whereas it is significantly reduced in those with abnormal liver biochemistry on treatment.
The two most important parameters in evaluating response to UDCA are ALP and total bilirubin. Qualitative and quantitative definitions of UDCA-response have been developed, based on changes of bilirubin, transaminases and ALP, after a time frame of 6 to 24 months of treatment with UDCA at 13-15 mg/kg/day. [39]
We are today also able to risk-stratify patients at diagnosis based on the probability of UDCA-response. This is relevant in order to early identify patients who would be eligible for second-line therapies before waiting for the treatment failure under UDCA, with potential impact on disease course. [40]
HCC is infrequent in PBC. Recent large-scale cohort studies highlighted as that the lack of UDCA-response after 12 months of therapy and male sex are associated with increased future risk of developing HCC in PBC.
After liver transplant, the recurrence of disease rate may be as high as 18 percent at five years, and up to 30 percent at 10 years. There is no consensus on risk factors for recurrence of the disease.[41]
Epidemiologic studies report heterogeneous incidence rates of 0.33 to 5.8 per 100.000 inhabitants per year, and prevalence rates of 1.9 to 40.2 per 100.000 inhabitants. Such figures, in particular the prevalence, have shown some increasing in the last decades. Improvement of diagnostic tools, increasing disease awareness, and digitalized patient registration with easing of case-findings, along with an improved survival likely contributed to the rising prevalence rates. The disease has been described worldwide, even though North America and Northern Europe have shown the highest incidence and prevalence rates. It is not clear whether there is a true variation in disease prevalence among populations of different geographical areas and of different ethnicity or if this is a consequence of a difference in study quality. [5] [6] PBC is more common in women, with a female:male ratio of at least 9:1. The peak incidence of PBC is in the fifth decade of life. In some areas of the US and UK, the prevalence is estimated to be as high as 1 in 4000. This is much more common than in South America or Africa, which may be due to better recognition in the US and UK. [5][6] First-degree relatives may have as much as a 500 times increase in prevalence, but there is debate if this risk is greater in the same generation relatives or the one that follows.
PBC is considered a prime example of the female preponderance in autoimmunity with a female to male ratio of up to 9:1, confirmed by large cohort studies, although some recent data, using administrative registries, suggest an increasing male prevalence. Major defects of sex chromosomes, i.e. enhanced monosomy X in female patients and an enhanced Y chromosome loss in male patients, have been described and might well explain the greater female predisposition to develop PBC. [42]
Even though there are case reports of patients diagnosed at the age of 15 or 93, the typical disease onset is between 30 and 60 years. It is estimated that prevalence of PBC in women over the age of 45 years could exceed 1 in 800 individuals.
The first report of the disease dates back 1851 by Addison and Gull who described a clinical picture of progressive jaundice in the absence of mechanical obstruction of the large bile ducts. Ahrens et al. in 1950 published the first detailed description of 17 patients with this condition and coined the term “primary biliary cirrhosis”. In 1959, Dame Sheila Sherlock reported a further series of PBC patients and recognised that the disease could be diagnosed in a pre-cirrhotic stage and proposed the term “chronic intrahepatic cholestasis” as more appropriate description of this disease. However, this nomenclature failed to gain acceptance and the term “primary biliary cirrhosis” lasted for decades. In 2014, to correct the inaccuracy and remove the social stigmata of cirrhosis as well as all the misunderstanding, disadvantages and discrimination emanating from this misnomer in daily life for patients, international liver associations agreed to rename the disease “primary biliary cholangitis”, as it is known nowadays.[43].[7] [44] [45]
The PBC Foundation is a UK-based international charity offering support and information to people with PBC, their families and friends.[46] It campaigns for increasing recognition of the disorder, improved diagnosis and treatments, and estimates over 8000 people are undiagnosed in the UK.[47][48] The Foundation has supported research into PBC including the development of the PBC-40 quality of life measure published in 2004[49] and helped establish the PBC Genetics Study.[17][50] It was founded by Collette Thain in 1996, after she was diagnosed with the condition.[47] Thain was awarded an MBE Order of the British Empire in 2004 for her work with the Foundation.[51] The PBC Foundation helped initiate the name change campaign in 2014.[8][9][52]
The PBCers Organization is a US-based non-profit patient support group that was founded by Linie Moore in 1996 and advocates for greater awareness of the disease and new treatments.[53] It has supported the initiative for a change in name.[9]
In 2014 the PBC Foundation, with the support of the PBCers Organization, the PBC Society (Canada)[54] and other patient groups, advocated a change in name from "primary biliary cirrhosis" to "primary biliary cholangitis," noting that most PBC patients did not have cirrhosis and that "cirrhosis" often had negative connotations of alcoholism.[8][9][52] Patient and professional groups were canvassed.[55] Support for the name change came from professional bodies including the American Association for the Study of Liver Diseases[56] and the European Association for the Study of the Liver.[57] Advocates for the name change published calls to adopt the new name in multiple hepatology journals in the fall of 2015.[55][57][58][59]
The AASLD Practice Guideline
| Classification | D
|
|---|---|
| External resources |
|
Diseases of the digestive system (primarily K20–K93, 530–579) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Upper GI tract |
| ||||||||||
| Lower GI tract: Intestinal/ Enteropathy |
| ||||||||||
| GI bleeding/BIS |
| ||||||||||
| Accessory |
| ||||||||||
| Abdominopelvic |
| ||||||||||
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
| リンク元 | 「原発性胆汁性胆管炎」「PBC」 |
| 関連記事 | 「primary」「biliary」 |
| Table 16-7. Main Features of Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis | ||
| Parameter | primary biliary cirrhosis | primary sclerosing cholangitis |
| Age | Median age 50 years (30-70) | Median age 30 years |
| Gender | 90% female | 70% male |
| Clinical course | Progressive | Unpredictable but progressive |
| Associated conditions | Sjogren syndrome (70%) | inflammatory bowel disease (70%) |
| scleroderma (5%) | pancreatitis (≦25%) | |
| thyroid disease (20%) | idiopathic fibrosing disease (retroperitoneal fibrosis) | |
| Serology | 95% AMA positive | 0% to 5% AMA positive (low titer) |
| 20% ANA positive | 6% ANA positive | |
| 60% ANCA positive | 82% ANCA positive | |
| Radiology | normal | strictures and beading of large bile ducts; pruning of smaller ducts |
| duct lesion | florid duct lesion; loss of small ducts | concentric periductal fibrosis; loss of small ducts |
| 自己免疫性肝炎 | 原発性胆汁性肝硬変 | ||
| AIH | PBC | ||
| 疫学 | 年齢 | 中年女性 | 中年女性 |
| HLA | HLA-DR4 | HLA-DR8 | |
| 自己抗体 | 抗核抗体 ANA | 抗ミトコンドリア抗体 AMA | |
| 抗平滑筋抗体 ASMA | |||
| 検査 | ↑血清IgG | ↑血清IgM | |
| 胆道系酵素上昇 | |||
| 合併症 | 各種自己免疫疾患 | Sjogren症候群 | |
| 関節リウマチ | |||
| 慢性甲状腺炎 | |||
| 強皮症 | |||
| 治療 | ステロイド | ウルソデオキシコール酸 | |
| 肝移植 | |||
| 禁忌 | ステロイド | ||
[★] 原発性胆汁性肝硬変 primary biliary cirrhosis → 原発性胆汁性胆管炎 primary biliary cholangitis